Selecta turns to synbio player for $1.1B capsid deal; BioNTech signs $790M immunotherapy deal

Selecta Biosciences has turned to one of the recent darlings in the synbio biz for its latest collaboration.

Ginkgo Bioworks has signed on to a biobucks-heavy deal to work on next-gen gene therapy viral capsids for Selecta, a hot topic in an industry that has identified...

Click to view original post